|
Higher risk for cervical cancer seen among women infected with multiple HPV types
July 11, 2006PHILADELPHIA — The risk for developing the tissue abnormalities, or lesions, that typically precede cervical cancer is much higher for women infected with multiple genotypes of the human papillomavirus (HPV) than previously reported, according to a study published in the July issue of Cancer Epidemiology, Biomarkers & Prevention.
Although doctors have known that the cervical tissue at the opening to the womb can harbor multiple HPV types, this study is the first to document that the risk for developing cervical cancer, the second most common form of cancer in women worldwide, is higher in females infected with multiple HPV types than those infected with just one HPV type.
In addition, the study's findings provide baseline data for analyzing over time the impact of the newly approved vaccine, Gardasil, on the dynamics of HPV infection.
"Women who harbor multiple infections are at higher risk for cervical lesions than those ever infected with one type only and should be followed more closely," said Eduardo L. Franco, Dr.PH., leader of the study and professor of epidemiology and oncology, and director, division of cancer epidemiology at McGill University.
Like previous studies on HPV in cervical cancer, the new research found that pre-cancerous abnormalities primarily occurred in women infected with HPV 16 and 18, the targets of Gardasil.
The vaccine also will prevent infection by the HPV types 6 and 11 that are associated with genital warts, and thus is expected to prevent cervical cancer in thousands of women.
However, the vaccine will not protect against HPV 58, which the new study discovered to be far more oncogenic than others when found in co-infections with other HPV types. The study's findings suggest HPV 58 should be one of the targets of the next generation of cervical cancer vaccines.
Indeed, the scientists discovered that the higher risk associated with HPV 58 in co-infections was similar to that conferred by HPV 16 in co-infections. Both HPV 58 and 16 "seemed particularly prone to increase risk" for pre-cancerous lesions in the cervix, said Helen Trottier, Ph.D., the first author of the research paper.
Participating in the study were 2,000 women, ages 18 to 40, most of whom were Caucasian and lived in Brazil. The team of scientists who conducted the study is based at McGill University in Canada and the Ludwig Institute for Cancer Research in Brazil.
The results suggest that the current method that doctors use for HPV screenings — the Papanicolaou cytology or "pap smear" — should be replaced with a test that detects the presence of a HPV co-infection and identifies each HPV genotype. If an infection is present, the current test cannot determine whether it was triggered by just one genotype or multiple types of HPV.
Because the HPV test used by Franco and his colleagues could detect more than 40 types of the virus and the presence of multiple infections, they could determine the specific genotypes of HPV present in the women's cervical tissue in single infections as well as co-infections.
The scientists theorized that the multiple viral infections could act synergistically to increase the pre-cancerous mutations or to expedite their progression to cancer. They also suggest that the presence of HPV co-infections may indicate that a woman's immune system is not particularly effective in clearing viruses.
This new research is the first prospective study using multiple measurements longitudinally to investigate the relationship between multiple HPV types and a woman's risk for developing pre-cancerous abnormalities in her cervix. During each of the 16,000 patient visits, both the pap smear and HPV tests were administered. The mean follow-up time of the study participants was over three years.
When Franco, Trottier and their colleagues analyzed the data about all patients (women who did not develop pre-cancerous cervical lesions as well as those who did), five HPV types emerged as the most common: 16, 53, 51, 31 and 18. HPV 16's high prevalence in infections was underscored by the scientists' analysis of the HPV types that were identified in all of the infections. HPV 16 was found in 9 to 14 percent of single and multiple infections respectively.
Just over 12 percent of the women tested during the first year were infected with multiple HPV types. Over four years, the total increased to more than 22 percent.None of the HPV types were more involved than other types in co-infections. In future studies, the scientists hope to pinpoint the particular combinations of HPV types that characterize the high-risk co-infections.
American Association for Cancer Research
"Women who harbor multiple infections are at higher risk for cervical lesions than those ever infected with one type only and should be followed more closely," said Eduardo L. Franco, Dr.PH., leader of the study and professor of epidemiology and oncology, and director, division of cancer epidemiology at McGill University.
Like previous studies on HPV in cervical cancer, the new research found that pre-cancerous abnormalities primarily occurred in women infected with HPV 16 and 18, the targets of Gardasil.
The vaccine also will prevent infection by the HPV types 6 and 11 that are associated with genital warts, and thus is expected to prevent cervical cancer in thousands of women.
However, the vaccine will not protect against HPV 58, which the new study discovered to be far more oncogenic than others when found in co-infections with other HPV types. The study's findings suggest HPV 58 should be one of the targets of the next generation of cervical cancer vaccines.
Indeed, the scientists discovered that the higher risk associated with HPV 58 in co-infections was similar to that conferred by HPV 16 in co-infections. Both HPV 58 and 16 "seemed particularly prone to increase risk" for pre-cancerous lesions in the cervix, said Helen Trottier, Ph.D., the first author of the research paper.
Participating in the study were 2,000 women, ages 18 to 40, most of whom were Caucasian and lived in Brazil. The team of scientists who conducted the study is based at McGill University in Canada and the Ludwig Institute for Cancer Research in Brazil.
The results suggest that the current method that doctors use for HPV screenings — the Papanicolaou cytology or "pap smear" — should be replaced with a test that detects the presence of a HPV co-infection and identifies each HPV genotype. If an infection is present, the current test cannot determine whether it was triggered by just one genotype or multiple types of HPV.
Because the HPV test used by Franco and his colleagues could detect more than 40 types of the virus and the presence of multiple infections, they could determine the specific genotypes of HPV present in the women's cervical tissue in single infections as well as co-infections.
The scientists theorized that the multiple viral infections could act synergistically to increase the pre-cancerous mutations or to expedite their progression to cancer. They also suggest that the presence of HPV co-infections may indicate that a woman's immune system is not particularly effective in clearing viruses.
This new research is the first prospective study using multiple measurements longitudinally to investigate the relationship between multiple HPV types and a woman's risk for developing pre-cancerous abnormalities in her cervix. During each of the 16,000 patient visits, both the pap smear and HPV tests were administered. The mean follow-up time of the study participants was over three years.
When Franco, Trottier and their colleagues analyzed the data about all patients (women who did not develop pre-cancerous cervical lesions as well as those who did), five HPV types emerged as the most common: 16, 53, 51, 31 and 18. HPV 16's high prevalence in infections was underscored by the scientists' analysis of the HPV types that were identified in all of the infections. HPV 16 was found in 9 to 14 percent of single and multiple infections respectively.
Just over 12 percent of the women tested during the first year were infected with multiple HPV types. Over four years, the total increased to more than 22 percent.None of the HPV types were more involved than other types in co-infections. In future studies, the scientists hope to pinpoint the particular combinations of HPV types that characterize the high-risk co-infections.
American Association for Cancer Research
Cervical Cancer News and Current Cervical Cancer Events RSSObese women in Canada are less likely to be screened for cervical cancer
Research in the United States has shown that obese people are less likely than their normal-weight peers to undergo screening for breast, colon and cervical cancer. Raj Padwal, Rebecca Mitchell and Scott Klarenbach, from the University of Alberta's Faculty of Medicine & Dentistry, have undertaken a study to see if this trend is also true in Canada.
New study shows potential to treat or prevent viral cancers
A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.
Avoiding Spleen Removal for Cooley's Anemia Sufferers
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia.
Estrogen Helps Drive Distinct, Aggressive Form of Prostate Cancer
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
UNC study firms up promise of potential new cervical cancer screening tool
New research into the causes of cervical cancer appears to lend weight to the promise of a potential early detection method that could help prevent the disease.
Mothers less likely to pursue HPV vaccination for youngest daughters
Because the first national study of its kind has found that U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it's incumbent upon the healthcare community to work to improve mom's acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children's Hospital Medical Center who conducted the study. HPV is a sexually transmitted virus known to cause cervical cancer.
Viruses may play a role in lung cancer development
Papers presented at the 1st European Lung Cancer Conference, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging evidence that common viruses may contribute to the development of lung cancer.
Phone counseling improves quality of life, immune systems of cervical cancer survivors
A unique telephone-counseling intervention not only improved the quality of life for cervical cancer survivors but also altered associated stress-related effects on their immune systems, a UC Irvine study has found.
American Cancer Society report details cancer prevention efforts
An annual report from the American Cancer Society highlights that long-term favorable trends have stalled for several factors that have been responsible for declining cancer death rates in the U.S.
Obesity may keep some women from getting screened for breast, cervical cancer
A review of cancer screening studies shows that white women who are obese are less likely than healthy weight women to get the recommended screenings for breast and cervical cancer, according to researchers at the University of North Carolina at Chapel Hill's School of Public Health.
More Cervical Cancer News Articles
| © 2008 BrightSurf.com |